DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR (desloratadine)
Desloratadine helps patients aged 12 and older manage the nasal and non-nasal symptoms associated with both seasonal and year-round allergies. It also treats chronic hives by reducing itching and the overall size and number of hives. This medication provides a long-acting option for individuals seeking relief from these persistent allergic reactions.
How DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR Works
This medication works by selectively binding to H1-receptors, which blocks histamine from triggering allergic symptoms. It also helps by inhibiting the release of histamine from mast cells. Research suggests the drug does not readily cross the blood-brain barrier, focusing its effects on peripheral histamine receptors.
Details
- Status
- Prescription
- First Approved
- 2011-04-26
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR Approval History
What DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR Treats
3 indicationsDESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is approved for 3 conditions since its original approval in 2011. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Seasonal Allergic Rhinitis
- Perennial Allergic Rhinitis
- Chronic Idiopathic Urticaria
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR
3 of 5FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07566351 | MDP.26.03.216 | Ph 2 | recruiting | Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis |
| NCT07486583 | MD-142-2025 | Ph 3 | not yet recruiting | Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. |
| NCT07333716 UC | 12/2025 TRop1 | Ph 2 | recruiting | Desloratadine in Patients With Ulcerative Colitis |
| NCT05214911 DESPRED | EF177 | Ph 3 | completed | Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children |
| NCT06916884 DESCUBRA | SIL-30810-III-23(1) | Ph 3 | recruiting | Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine |
| NCT01916967 results posted | 4117-201 132243 | Ph 3 | completed | An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) |
| NCT02646020 EGFR-TKIs | TAPE001 | Ph 2 | completed | Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment |
| NCT02507635 | 535 | Ph 4 | completed | Anti-inflammatory H1 Antihistamines Allergic Rhinitis |
| NCT01985789 | PHPY2013/14 | Ph 4 | completed | Anti-histamines and Methacholine Challenges. |
| NCT01400828 | YCD159 | Ph 3 | completed | Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis |
| NCT01940393 | GACE-01 | Ph 4 | completed | Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria |
| NCT01444196 AECUDATT | 2008-005746-22 2008-005746-22 | Ph 4 | completed | Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR FDA Label Details
Indications & Usage
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR is indicated for the treatment of Seasonal Allergic Rhinitis; Perennial Allergic Rhinitis; Chronic Idiopathic Urticaria.
Track DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.